SCHEMBL3560104

SCHEMBL3560104

CCc1cc2ccccc2c([O])c1CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
MAPT P10636 1/20 0.40
HTR2A P28223 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
TSHR P16473 1/20 0.37
APAF1 O14727 1/20 0.36
CASP3 P42574 1/20 0.36
CASP6 P55212 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
NCEH1 Q6PIU2 1/20 0.36
HIF1A Q16665 1/20 0.35
CYP1B1 Q16678 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2A6 P11509 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2126142 0.84 HTR2A (0.47) ATMALDH1A1KDM4EMAPTHTR2A
Lithium SCHEMBL9194981 0.82 HTR2A (0.45) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL9194974 0.82 HTR2A (0.45) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL2126035 0.81 ATM (0.41) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL3555195 0.80 GPR84 (0.49) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL3892477 0.79 HTR2A (0.42) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL3957770 0.79 POLB (0.44) ATMGPR84CASP6NCEH1ME2
SCHEMBL8517709 0.79 ATM (0.41) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL8374997 0.78 ATM (0.43) ATMALDH1A1KDM4EMAPTHTR2A
SCHEMBL8372799 0.78 ATM (0.43) ATMALDH1A1KDM4EMAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
US-7659276-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2010-02-09 US disclosed
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2009-06-04 US disclosed
US-7514438-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP disclosed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP disclosed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US disclosed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST MCHR1, MC1R, NPY1R ATM 2387/4885ALDH1A1 2113/4885KDM4E 3530/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R ATM 2387/4885ALDH1A1 2113/4885KDM4E 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.